A new and more effective oral obesity drug Amycretin for weight loss

Amycretin, a new oral drug in development for the treatment of obesity, has received a lot of attention for its superior weight loss results over Semaglutide after 12 weeks. In this blog, we’ll talk about how Amycretin works and it’s benefits in weight loss.

Know Amycretin peptide?

Amycretin, a GLP-1 receptor agonist and amylin receptor agonist, is a short-chain amino acid peptide that mainly affects the body’s metabolism and appetite to achieve weight loss.

GLP-1 agonist, which mimics the GLP-1 hormone produced by the proglucagon gene in L cells of the small intestine. Amycretin stimulates GLP-1 receptors, causes appetite loss, slows stomach emptying, helps increase feelings of fullness and reduces calorie intake, thereby aiding weight loss.

Amylin is produce primarily by beta cells in the pancreas and is release at the same time as insulin, which is also locate in the pancreas. Amylin links to appetite, weight, and blood sugar levels, and when it release into the bloodstream, it activates various homeostasis and reward centers in the brain to suppress appetite and reduce food intake.

Amycretin encourages the body to consume less food and use more energy, which promotes weight loss. By reducing appetite and increasing energy expenditure, this peptide can help people manage their weight more effectively. It can also promote healthier eating habits by reducing cravings for excessive food consumption. In addition to these benefits, Amycretin may also have a positive effect on blood sugar levels, which is especially beneficial for people with diabetes.

Amycretin in weight loss: Amycretin vs semaglutide

There are several weight loss drugs base on GLP-1 receptor agonists, and Semaglutide and Liraglutide are both FDA-approve weight loss drugs that are GLP-1 receptor agonists.

Amycretin is developed by the same company as Semaglutide, which has been approved by the FDA, and Amycretin, a new weight loss drug in development. Since Amycretin vs Semaglutide are both GLP-1 agonists, why did the company start a new weight-loss drug, Amycretin, after Semaglutide had been successful?

Amycretin weight loss clinical trial

Amycretin has only completed a Phase I clinical trial. In the Phase I trial of Amycretin, an oral dose was used in 144 participants over a 12-week period. After 12 weeks, participants using Amycretin lost 13.1 percent of their body weight and those using placebo lost 1.1 percent.

Amycretin VS semaglutide

In the Semaglutide clinical trial, participants lost 6 percent of their body weight after 12 weeks and 15 percent after 68 weeks. Therefore, Amycretin Vs semaglutide, and the weight loss effect of Amycretin at 12 weeks was significantly better than that of Semaglutide. This is one of the main reasons Amycretin is getting a lot of attention.

Amycretin is orally taken

Amycretin is easier to use when taken orally than by injection, which is another reason for concern. Semaglutide is for injection, and while it is good for weight loss, there is a subset of people who are afraid of needles and injections. Injections are also more likely to cause discomfort at the injection site. Oral Amycretin will bring greater convenience, and its weight loss effect is so good.

Amycretin in weight loss safety

Amycretin has only completed a Phase I clinical trial, and its safety has not been proven. But in Amycretin’s Phase I clinical trial, more than 80 percent of participants were still taking the drug to lose weight after 12 weeks. This is a high retention rate, which to some extent indicates the safety of its dose. It also gives people confidence in late-stage trials.

Amycretin dosage in weight loss

There is no exact dose of Amycretin, but the highest dose in the Amycretin trial was 50mg-100mg per day, equivalent to 350-700mg per week. The daily dose will vary depending on your doctor’s advice and your personal situation. Typically, the initial dose is 30 mg per day. However, in actual use, we may need to adjust according to the specific situation of patients.

Amycretin review

Amycretin represents a promising new option for obesity management, especially for patients who prefer oral medications to injections. Its comparable efficacy in weight loss and blood sugar control, combined with the ease of oral administration, makes it a potentially better alternative to semaglutide for many patients.

Continued research and real-world studies will further clarify its long-term benefits and safety, potentially applying it to a broader patient population and solidifying its role in the fight against obesity.